Darlene Kirk, CCRP, for aid in coordinating the study and preparing the manuscript. and C57BL/6) or given live virus, influenza vaccine, or PBS suggesting infection occurred in all. Histopathology seen in animals given one of the SARS-CoV vaccines was uniformly a Th2-type immunopathology with prominent eosinophil infiltration, confirmed with special eosinophil stains. The pathologic changes seen in all control groups lacked the eosinophil prominence. Conclusions maslinic acid These SARS-CoV vaccines all induced antibody and protection against contamination with SARS-CoV. However, challenge of mice given any of the vaccines led to occurrence of Th2-type immunopathology suggesting hypersensitivity to SARS-CoV components was induced. Caution in proceeding to application of a SARS-CoV vaccine in humans is indicated. Introduction Severe acute respiratory syndrome (SARS) emerged in Guangdong, People’s Republic of China, in late 2002, and spread to other countries in Asia and to Canada in the ensuing months [1]C[3]. Contamination control efforts brought the infection under control by mid-2003 [4]. More than 8000 cases, including almost 800 deaths, were reported during the outbreak period [4]. Increasing age and comorbidity were risk factors for severe disease and death [5], [6], [7]. Since 2003, only sporadic cases have been reported; however, the possibility that SARS outbreaks could reemerge naturally or be deliberately released is usually a public health concern. SARS is caused by a Coronavirus (SARS-CoV) [8], [9]. Limited data are available about the ecology of SARS-CoV, but bats are thought to be the animal maslinic acid reservoir for the virus which may be transmitted to small mammals with exposure to these small animals as the source of human infections [10]. The clinical disease is similar to other severe acute respiratory infections, including influenza; the SARS case definition includes clinical, epidemiologic, and laboratory criteria [11], [12]. A number of therapeutic efforts were employed for the disease in Asia and in Canada; however, no treatment of clear value was identified. Animal models were developed using mice, hamsters, ferrets and nonhuman primates, and efforts to identify useful treatments and effective vaccines are ongoing. Vaccine candidates for preventing SARS have been developed by various groups and include inactivated whole virus, spike (S) protein preparations, virus-like particles (VLPs), plasmid DNA and a number of vectors made up of genes for SARS-CoV proteins [13]C[28]. Phase I studies in humans have been conducted with a whole virus vaccine and a DNA vaccine [29]C[30]. An early concern for application of a SARS-CoV maslinic acid vaccine was the experience with other coronavirus infections which induced enhanced disease and immunopathology in animals when challenged with infectious virus [31], a concern reinforced by the report that animals given an alum adjuvanted SARS vaccine and subsequently challenged with SARS-CoV exhibited an immunopathologic lung reaction reminiscent of that described for respiratory syncytial virus (RSV) in infants and in animal models given RSV vaccine and challenged naturally PR65A (infants) or artificially (animals) with RSV [32], [33]. We and others described a similar immunopathologic reaction in mice vaccinated with a SARS-CoV vaccine and subsequently challenged with SARS-CoV [18], [20], [21], [28]. It has been proposed that this nucleocapsid protein of SARS-CoV is the antigen to which the immunopathologic reaction is usually directed [18], [21]. Thus, concern for proceeding to humans with candidate SARS-CoV vaccines emerged from these various observations. The studies reported here were conducted to evaluate the safety, immunogenicity, and efficacy of different SARS-CoV vaccines in a murine model of SARS. Materials and Methods Tissue Cultures and Virus Vero E6 tissue cultures [obtained from The American Type Culture Collection (ATCC), CRL:1586] were produced in Dulbecco’s modified minimum essential medium (DMEM) supplemented with penicillin (100 units/ml), streptomycin (100 g/ml), 0.2% sodium bicarbonate and 10% fetal bovine serum (FBS). The Urbani strain of SARS-CoV was obtained from T.G. Ksiazek at the Centers for Disease Control.
Categories